trial

Novel Anti-Fibrotic Drug AK3280 Cleared by FDA to Initiate Phase 2 Proof-of-Concept Clinical Trial in IPF

SHANGHAI, Feb. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug…

17 hours ago

Industry First! HTX Launches the New Funds Bonus Trial Program, Offering Rewards of Up to 20%

PANAMA CITY, Feb. 11, 2026 /PRNewswire/ -- On February 6, 2026, HTX officially launched the industry's first "New Funds Bonus Trial…

1 day ago

Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma

February 11, 2026 06:00 ET  | Source: Upstream Bio – Verekitug provided statistically significant and clinically meaningful reductions in annualized…

1 day ago

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer’s Disease

TAINAN, Feb. 10, 2026 /PRNewswire/ -- MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced positive…

3 days ago

Dewpoint Therapeutics Doses First Patient in Phase 1a/2a Trial DPTX3186 for the Treatment of Advanced Solid Tumors, Focused on Gastric Cancer

DPTX3186, a first-in-class beta-catenin condensate modulator, received Orphan Drug Designation and Fast Track Designation from FDAClinical entry validates condensate modulator…

1 week ago

Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04

February 04, 2026 09:35 ET  | Source: Adial Pharmaceuticals, Inc GLEN ALLEN, Va., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Adial…

1 week ago

Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating NEO-811 For the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platform February 03, 2026 13:08 ET  | Source:…

1 week ago

Skyhawk Therapeutics Announces Nine Month Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease

Nine-month findings show mean improvement in Composite Unified Huntington's Disease Rating Scale from baseline of +0.64 points, compared to natural…

2 weeks ago

Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)

First in class study of an investigational ACTH receptor antagonist aims to address significant unmet need in children and adolescents…

3 weeks ago

Nxera Pharma Reports Positive Results From Phase 3 Trial of Daridorexant in South Korea

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia and…

3 weeks ago